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Abstract New incidence of prostate cancer is a major public health issue in the Western world, and has been rising 
in other areas of the globe in recent years. In an effort to understanding the molecular pathogenesis of this disease, 
numerous cell models have been developed, arising mostly from patient biopsies. The introduction of the genetically 
engineered mouse in biomedical research has allowed the development of murine models that allow for the investigation 
of tumorigenic and metastatic processes. Current challenges to the field include lack of an animal model that faithfully 
recapitulates bone metastasis of prostate cancer.
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Introduction
The incidence of prostate cancer (PCa) is one of the most prevalent 
cancer diagnoses throughout the world, and is one of the most intensely 
studied problems in human disease. According to the American Cancer 
Society, in 2014 there were over 233,000 new cases of PCa diagnosed 
in the US, resulting in about 29,340 deaths [1]. As cancer is a disease 
of aging, prostate lesions occur infrequently before the age of 40, with 
the peak incidence occurring between the age of 70–74 [2]. According 
to the World Health Organization (WHO)’s International Agency for 
Research on Cancer, the cancer incidence on five continents indicates 
that the age standardized incidence rate (ASIR) of PCa among some 
Asian populations has increased from nearly three to over fifty fold in 
places such as Hong Kong and Shanghai [3].
The etiology of PCa has remained a puzzling issue. A strong cor-
relation exists with age, with increased relative risk for individuals 
with a family history [4]. African-American men are at significantly 
higher incidence, with one recent study citing a 12% increase in the 
proportion of an African-American cohort with multiple positive bi-
opsy cores compared to a White-American cohort [5]. Environmental 
risk factors, which have been quantified in adoption studies at 4.8%, 
include the consumption of long chain polyunsaturated fatty acids 
found in smoked or over-cooked fish, vitamin D deficiency in people 
with reduced tanning potential, and dietary factors such as intake of red 
meat [6-9]. Smoking may also put individuals at increased risk for PCa, 
and sexually transmitted diseases have been identified as a risk factor 
[10,11]. Inflammatory factors have been implicated in the development 
of PCa, such as bacterial toxins and exogenous carcinogens such as 
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine or PhIP [12,13].
There is a discussion in the field regarding the specificity of the 
prostate specific antigen (PSA) test as a useful prognostic indicator 
of potential metastatic castration resistant prostate cancer (mCRPC), 
with some saying that widespread epidemiological screening does not 
justify the modest decrease in cancer death [14-16]. In the new para-
digm of “predict, prevent, and personalize” medicine, understanding 
the molecular phenotype and pathogenesis of disease will allow for 
more accurate and precise treatment of PCa
In vitro model systems
By far the most useful in vitro model that we have of PCa is cell 
culture. The sheer number of cell lines that are available for study is 
expansive, due to the fact that PCa can arise from one of several cell 
sources in the prostate. In addition to the information contained in this 
review, a good cell line database is available from the British Columbia 
(BC) Cancer Agency [17]. A comprehensive and exhaustive two-part 
compendium of PCa cell lines is available from Sobel and Sadar [18,19]. 
All information is derived from the BC Cancer Agency Prostate Can-
cer Cell Line Database cited previously unless otherwise specified. A 
summary is available in Table 1.
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DU-145
Along with LNCaP and PC3 cells, DU-145 cells were once considered 
part of the triad that constituted the gold standard of PCa cell culture 
lines. DU-145 cells were first isolated from a brain metastatic prostate 
tumor in 1975 [20]. The isolation of this line represented an answer 
to the criticism of then existing cell lines MA 160 and EB 33, both of 
which represented cell isolated from admixtures of benign tumor or 
moderately differentiated adenocarcinoma. It is hormone independent 
and does not express androgen receptor (AR) mRNA/protein or PSA 
mRNA/protein. This observation has brought this cell line into disfavor 
among investigators. The vast majority of human prostate tumors express 
AR, so some would contend that this is a model that does not faithfully 
mimic human disease [21]. This is an important consideration, as the 
selection of this cell line for experimentation such as studies that seek 
to test the effect of hormone status would be futile on this model. In 
addition to absent AR, this line demonstrates a heterozygous P223L/
V274F p53 expression pattern, changing its transcriptional program 
[22]. Phosphatase and tensin homolog (PTEN) expression is hetero-
zygous [23]. This line contains marker chromosomes M1, M2, and M3. 
Its karyotype ranges from 46 to 143 (modal of 64) with a metacentric 
Yq+ chromosome. This cell line’s doubling time is established at 34 
hours [24].
An important consideration in the selection of a PCa cell model 
is growth rate and behavior as a xenograft. DU-145 cells maintain 
phenotype and genotype when injected into mice and metastasize to 
a variety of organs, including spleen, lung, and liver [25,26]. Tumor 
growth in SCID mice has a 7-day latency with a biphasic growth rate 
of 5.5 for doubling in days 7–14 and 8.5 days for doubling after day 
14 when placed without sponge material [27].
The response to growth factors is another important consideration to 
make when choosing a PCa cell line as growth factor independence via 
autocrine signaling has been defined as one of the hallmarks of cancer 
[28]. A substantial amount of work has been done on the effect of growth 
factors on this cell line. Of particular note is the increased expression 
of TGF-α and IGF-1 [29,30]. More information on the growth factors 
and growth factor receptor expression profile is available in Table 1.
Investigators have recently started to interrogate the role of energy 
metabolism in the role of PCa carcinogenesis. One of the main factors 
in energy metabolism is liver kinase B1 (LKB1, also referred to as ser-
ine/threonine kinase 11; STK11), an upstream kinase of Wnt/β-catenin 
and Hedgehog signaling pathway targets [31,32]. Recent work done 
on glucose deprivation and activation of AMP-activated protein kinase 
by vascular endothelial growth factor detected an absence of LKB1 in 
this cell line [33].
As a final note, one of the obvious goals of cancer treatment is to 
induce cancer cells into apoptosis and thus decreased tumor bulk. Pro- 
and anti-apoptotic proteins are delicately balanced in non-cancerous cells 
but can become deranged in cancer settings. An important consideration 
to make using DU-145 cells as an in vitro model system is the presence 
of the pro-apoptotic protein Bax. The expression of Bax in this cell line 
has been debatable. An older report by Shirahama et al. indicates the 
expression of Bax in this line [34], but the bulk of subsequent literature 
seems to indicate its absence [35-37]. It is recommended that Western 
blot analysis on this line’s Bax expression be conducted prior to utili-
zation as a research model.
PC3
PC3 cells were isolated from a vertebral metastatic prostate tumor 
in 1979 in answer to the concern that few lines were available that were 
entirely composed of carcinoma cells [38]. This cell line is similar to 
DU-145 cells in that it is hormone insensitive and presents no AR or 
PSA mRNA/protein, bringing it into similarly marginal favor with 
some investigators. As a highly aneuploid line, its karyotype has a 
modal number of 58 with a doubling time of approximately 33 hours. 
Among the interesting observations made about this cell line is the 
expression of transferrin receptor and growth stimulation by treatment 
with bone marrow derived transferrin [39,40]. Autonomous growth can 
be attributed to high expression levels of TGF-α and EGF-R [41]. This 
has led some investigators to speculate that this is one factor that makes 
bone a hospitable metastatic site. It expresses aberrant p53 with a C 
deletion in codon 138 causing a nonsense codon at 169 (causing a loss 
of heterozygosity) and is PTEN deficient [42,43]. Little information is 
available on xenograft growth rates, but our experience with intratibial 
cancer cell inoculations suggests it is similar to DU-145 cells with latency 
of approximately one week and doubling times in the range of 4–5 days. 
Of important note to investigators working with PC3 cells is the recent 
observation that this line is more characteristic of neuroendocrine, or 
small cell, carcinoma rather than adenocarcinoma [44].
LNCaP
As the lynchpin for numerous subsequent derivatives, LNCaP cells 
were first isolated from a human metastatic prostate adenocarcinoma 
found in a lymph node [45]. The original LNCaP cell line is androgen 
responsive with AR and PSA mRNA/protein expression. Of particular 
note, this cell line contains a T877A mutation in the AR coding sequence 
that gives it promiscuous binding affinity to a range of steroid com-
pounds [46]. This slow growing cell line doubles every 60–72 hours 
(depending on serum concentration) and has a karyotype of 33 to 91 
chromosomes (modal of 76–91). They are responsive to TGF-α, EGF 
and IGF-1, and express EGF/TGF-α-R, FGF-R, and IGF-1-R [47,48]. 
Of note is the expression of cytokeratins (CK) 8, 18, and 20, wild type 
(WT) p53 and PTEN inactivation [49-51]. Xenografting demonstrates a 
modest 50% success rate with a tumor doubling time of 86 hours when 
combined with a Matrigel™ formulation [18].
C4-2B
These cells were isolated from a mouse vertebral metastasis in 1994 
as a subline of LNCaP xenografts, a derivation of a previous cell line 
established by Wu et al [52]. The C4 line was generated using subcuta-
neous co-injection of LNCaP and human osteosarcoma MS cells. Mice 
were then castrated to drive the tumors into androgen independence, 
and subsequent tumor cells were cultured and termed C4. The C4 cells 
were then subcutaneously co-injected into a castrated mouse. Then, the 
tumor cells were cultured from the tumors formed and termed C4-2. 
These cells were then subcutaneously or orthotopically injected into 
castrated mice, with subsequent surveillance for metastasis. Several 
metastases were detected, with one metastasis spreading to the bone. 
These bone metastatic cancer cells were finally isolated and termed 
C4-2B [53]. The authors who initially isolated this line have noted that 
castrated mice have a higher incidence of bone metastasis than do intact 
mice. Karyotyping ranges from 61–90 chromosomes (modal of 83) in 
the C4 line with a doubling time of 48 hours for C4-2B specifically.
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They express AR and PSA mRNA/protein. These cells express low 
levels of p53 and are PTEN null [54]. This line consistently grows in 
either intact or castrated mice
LAPC-4
This cell line was introduced in 1997 and was the result of a series of 
subcutaneous xenografting experiments into SCID mice [55]. Explants 
from 6 of 8 Los Angeles prostate cancer (LAPC) patients were found 
to sustain growth very well in mice, doubling or tripling in volume. 
After several passages, several of the explants did not demonstrate 
detectable levels of human β-globin, and thus were deemed overrun 
by murine cells. This left only two explants, LAPC-3 and LAPC-4, as 
the sole survivors of the initial experiment. Of the two, LAPC-4 was 
the only cell line that retained its androgen dependence. Cytogenetics 
shows a range of 79–92 chromosomes (modal of 89) with loss of the 
Y chromosome. Doubling rate was calculated at around 72 hours. 
They are positive for AR/PSA mRNA/protein with P72R and R175H 
mutations in the p53 gene and express WT PTEN [56]. A mutation in 
the tumor protein 53 (TP53) gene causes an A175H mutation in p53. 
They can grow subcutaneously, orthotopically, or intratibially in mice 
[57]. Orthotopic inoculation tends to metastasize more frequently, while 
intratibial injection demonstrates an osteoblastic phenotype, mimicking 
frequent osteoblastic lesions found in humans
LAPC 9
These cells were first isolated from a femoral metastasis that formed 
in a patient undergoing androgen ablation therapy in 1999 [58]. Devel-
oped by the same group that isolated LAPC-4, it is a response to the 
need for an androgen sensitive counterpart. It is WT AR/PSA positive 
and will form tumors through subcutaneous injection in intact mice 
with as few as 10 cells. However, the investigators report that only 
a fraction of such injections will form tumors in castrated mice. A 
result of serial passaging in SCID mice, tumor-volume doubling time 
is approximately three weeks. These cells undergo growth arrest upon 
the removal of androgen but will retain sensitivity for up to 6 months 
post-removal. A very small subpopulation of cells was found to express 
cytokeratin 5 [59].
VCaP
These cells were first isolated in 2001, as the result of a vertebral 
metastatic lesion utilizing a procurement team designed to implement 
“warm” autopsies [60,61]. The cell line is positive for androgen sensi-
tivity with wild-type AR mRNA/protein, and expresses PSA mRNA/
protein, in addition to expressing prostatic acid phosphatase (PAP), 
retinoblastoma (Rb) and p53 (with an A248W mutation due to a mutation 
in TP53). Doubling time is 5 to 6 days and cytogenetics demonstrates 
a range of hypodiploid to hypertriploid genomes. PTEN remains intact 
in this cell line. These cells grow well in intact mice (doubling time 
of 10 days) as well as castrated mice (doubling time of 13 days) [18]. 
An important consideration to make in early PCa invasion is the role 
of the transmembrane protease, serine 2–ETS regulated gene (TM-
PRSS2-ERG) gene rearrangement. This translocation occurs when the 
3’ end of ERG (21q22.3), ETV1 (7p21.2), or ETV4 (17q21) is added 
to the 5’ end of the androgen responsive TMPRSS2 gene, creating an 
androgen-responsive oncoprotein [62]. VCaP cell line is one of the few 
PCa cell lines to demonstrate at least one copy of this rearrangement.
22Rv1
22Rv1 is a cell line that is representative of prostate carcinoma intro-
duced in 1999 [63]. This line was isolated from the xenograft CWR22R 
that was isolated from a patient with bone metastasis. 22Rv1 was 
developed by plating CWR22R on irradiated feeder cells, trypsinized, 
and isolated via CD44 staining. Two successive regrowths on feeder 
cells allowed for the isolation of this line. Doubling time ranges from 
35–40 hours. Cytogenetic analysis reveals a hyperdiploid genome in 
early passages but will expand to a stable tetraploid state as passaging 
continues. It consistently demonstrates trisomy for chromosomes 7, 
8, and 12. It is positive for AR mRNA/protein and PSA mRNA, but 
negative for PSA protein. It is responsive to EGF, but it is not inhibited 
by TGF-β. It expresses WT PTEN [64-66]. This model is of particular 
interest to investigators researching AR splice variants. Variants that 
activate in a ligand independent manner have been identified as one of 
the main players in hormone refractory tumor progression [67]. Two 
such variants have been identified as being expressed endogenously in 
22Rv1, specifically a full length isoform with an exon 3 duplication and 
C terminal domain truncations with aberrant exon 2b expression [68].
ARCaP
ARCaP was first introduced by Zhau et al. in 1996 and is also referred 
to as MDA PCa 1 [69]. First isolated from the ascites fluid of a patient 
with metastatic disease, it is highly metastatic with hallmarks of ade-
nocarcinoma expression patterns of low AR mRNA and PSA mRNA/
protein, with additional markers suggesting selective neuroendocrine 
differentiation. It expresses a H847Y AR variant and a Q331R p53 
variant. This line has a take (or engraftment) rate of 100% in intact or 
castrated nude mice. A surprising observation is that tumors grow three 
times faster in castrated mice than in intact mice. Treatment with steroid 
compounds in vitro inhibits growth as well. TP53 analysis reveals a 
loss of heterozygosity and an A196end mutation [18].
MDA PCa 2a/2b
These two cell lines were derived from a single patient with vertebral 
metastasis during late stage disease in 1997 [70]. These are one of the 
few cells lines that were isolated from an African-American patient. 
Coming from two different areas of the same lesion, they are both an-
drogen sensitive and tumorigenic in mice, with the 2a form doubling in 
82–93 hours and the 2b form doubling in 42–73 hours, depending on 
the passage number. Different growth rate indicates that these two lines 
are clones from different cells within the same lesion. The karyotypes 
are 49–92 (modal of 63) for 2a and 44–92 (modal of 47) for 2b. The 
2a form has a higher incidence of chromosomal abnormalities with a 
tetraploid genome. The 2b form has unique genomic characteristics, 
demonstrating a near diploid karyotype during early passages but expands 
to near tetraploid at passage 36. This observable change indicates that 
these alterations are a product of in vitro passaging and not the result 
of a polyclonal population of cells derived from the patient sample. 
Both cell lines exhibit WT TP53, express AR mRNA/protein with 2 
mutations in the ligand-binding domain of MDA PCa 2a (L701H and 
T877A), and express PSA mRNA/protein [71,72]. One dichotomizing 
factor between the 2a and 2b forms is the presence of Bax in only 2a. 
The take rate in mice is increased with the addition of Matrigel™. The 
2b form grows faster than the 2a in vivo, although 2a is the only one of 
the two to form palpable intraprostatic tumors after 11 weeks. PTEN is 
intact [73]. When used in conjunction, this model is referred to as MDA 
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PCa 2 (two) a and 2b bone metastases model (TabBO).
RWPE-2
It is a genetically modified form of the human normal prostatic ep-
ithelium cell line RWPE-1 (discussed below). Ki-ras gene and human 
papilloma virus 18 (HPV) genome were introduced into the RWPE-1 
line, making it tumorigenic [74,75]. It is positive for AR and PSA 
mRNA/protein, and is described as hormone sensitive but not hormone 
dependent. It will grow in vitro appreciably without androgens, but will 
increase proliferation in their presence. This line expresses cytokeratins 
8 and 18 and has a 48–54 chromosome karyotype (modal of 51). A 
unique trait about this line is the nucleus stains very strongly for WT 
p53 and Rb. It responds very well to EGF treatment and is inhibited 
by TGF-β. An injection of one million cells subcutaneously will form 
undifferentiated tumors in nude mice with a latency of 3–4 weeks. Since 
it has been immortalized with HPV, it strongly expresses the viral protein 
E7. Of special consideration is the fact that HPV DNA is found in up to 
90% of cervical, vulvar, penile, and perianal cancers [76]. This makes 
RWPE-2 an important model for studying the potential role of viral 
factors in the transformation of prostate epithelium into carcinomas.
LuCaP
Similar to MDA PCa 2a and 2b, LuCaP cells are the result of three 
successful xenografts from a single patient at autopsy. LuCaP 23.1 
and 23.8 were isolated from lymph node metastases and 23.12 was 
isolated from a liver metastasis in response to the need for cell lines that 
faithfully model prostate carcinoma [77]. The patient was a 63 year old 
Caucasian and had undergone radiation, orchiectomy, and chemotherapy. 
The chromosome range is 62–112 (modal of 78). Retaining androgen 
sensitivity and responsiveness, these cells do not grow in culture but 
must be maintained in mouse hosts via serial transplantation [19]. 
Volume doubling time in mice is 11, 15, and 21 days for 23.1, 23.8, 
and 23.12, respectively.
Non-tumor prostatic epithelial lines
RWPE-1
In comparison to the cancer cell lines discussed previously, non-tum-
origenic human prostatic epithelium (HPE) cell lines are used as a way 
to contrast PCa pathogenesis. The most prevalent of this type of cell 
lines is RWPE-1. These cells were immortalized with human papilloma 
virus (HPV) 18 with subsequent isolation and propagation over 6–7 
weeks [78,79]. This cell line is positive for AR/PSA mRNA/protein and 
is androgen sensitive, which was specifically developed to address the 
problem of normal prostatic epithelial growth and development [74]. 
It responds normally to EGF and TGF-β treatment and does not form 
tumors in mice. Benign prostatic hyperplasia (BPH) is an inflammatory 
condition that generates reactive oxygen species (ROS) and recent studies 
have tried to make a link connecting BPH to neoplasia [80]. BPH is a 
common condition among men in their sixth decade, with about 50% 
of that population demonstrating symptoms. RWPE-1 is therefore a 
good model to investigate the molecular mechanisms underlying the 
proliferation of benign prostatic epithelial cells.
BPH1
Hayward et al. isolated this cell line from benign prostatic hypertrophy 
or hyperplasia (BPH) tissues obtained through transurethral resection 
from a 68 year old patient undergoing the procedure for urinary ob-
struction consistent with BPH in 1994 [81]. Histologically benign, these 
cells were cultured out of the surgical specimen and immortalized, but 
not transformed, with the SV40 large T antigen. Karyotype analysis 
shows an aneuploid genome, with a range of 71–79 (modal of 76). 
Cells were viable but non-tumorigenic in mice. They are EGF, TGF-α, 
and FGF1/7 responsive, and are inhibited by FGF2 and TGF-β1/2 with 
androgen insensitivity. They are AR/PSA negative and WT p53 positive. 
It expresses PTEN, p21Cip1/Waf1, and Bax [82,83]. Doubling time is 
approximately 35 hours.
pRNS-1-1
This is another type of HPE cell introduced into the literature in 1994 
[84]. This line has been immortalized, to at least 50 passages, with the 
pRSV-T plasmid, which contains an origin-defective SV40 genome 
and the rous sarcoma virus long terminal repeat (LTR) along with a 
neomycin resistance gene. It expresses cytokeratins 5 and 8, responds 
normally to typical growth signals (EGF, IGF, pituitary extract) and 
inhibitory signals (retinoic acid, TGF-β). However, investigation by Lee 
and colleagues seemed to indicate that these cells lost responsiveness to 
growth inhibitory signals such as TNF-α and vitamin D3, indicating the 
ability of this line to transform. This cell line has a karyotype of modal 
chromosome number of 49–52 with a doubling time of approximately 
72 hours. PSA was detected in patient and early passage samples, but 
lost expression during later passages. An interesting observation made 
by Brinkmann and colleagues found these cells form normal prostatic 
glandular structures from cellular aggregates when treated with he-
patocyte growth factor/scatter factor (HGF/SF) [85]. These aggregates 
would usually collapse after about a week in culture.
An important footnote in the story of pRNS-1-1 cells is the develop-
ment of WPMY-1, isolated and developed by the same group and from 
the same prostate that gave us pRNS-1-1 [79]. This is a non-neoplastic 
stromal cell line that allows for the investigation of stromal/epithelial 
interactions in the development of PCa. Significant investigation is being 
conducted in the potential role that stromal cells play in the transition 
from hormone sensitive to castration resistant PCa [86].
PIN
No review of PCa cell lines would be complete without at least a 
mention of prostatic intraepithelial neoplasia (PIN). This is a condition 
that has been identified as a premalignant lesion in the development of 
PCa [87,88]. PIN cells are thus an important cell line for the investiga-
tion of oncogenic processes and molecules in a premalignant context. 
Developed and introduced into the literature in 1999 by Stearns and 
colleagues, this is a line isolated from an African-American patient 
[89]. The same HPV-18 construct used to immortalize RWPE-1 cells 
was also used to immortalize this cell line. The authors described this 
line in detail at passages 5 and 15, demonstrating PSA production via 
stimulation with DHT and dihydroxyepiandosterone at passage 5 but 
moving on to androgen insensitivity at passage 15. They also note that 
early passage cells expressed CK18 and 34βE12, but later passages lost 
detection of 34βE12. They indicated this as basal cell origin with no 
contribution from nearby cancer tissue. This group also looked at the 
role of interleukin-10 (IL-10), activin A, and inhibin (both members of 
the TGF-β superfamily) in this line’s proliferative ability. They noted 
the ability of activin to stimulate growth even as TGF-β was able to 
reduce growth. Also noted is the ability of activin A to inhibit growth 
when present in culture media with IL-10. They also postulated that 
activin A blocks growth of these high grade PIN lesion cells by binding 
follistatin, thus preventing IL-10 growth stimulation. Xenograft studies 
revealed an inability of these cells to grow in mice.
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In vivo model systems
Since the initial use of the mouse model in biomedical research nearly 
a century ago, scientists have gone from techniques as simple as cross 
breeding in a desired trait to selectively manipulating the genome to 
induce a disease state. PCa understanding has benefitted tremendously 
from the use of these techniques, particularly through the use of the 
mouse models detailed below. The need for in vivo models was an 
outgrowth of the understanding that cancer cell lines in general (and 
prostate lines in particular) do not and cannot recapitulate the disease 
processes that occur in living tissues. Teasing apart molecular interactions 
and alterations in cancer cells is of incredible worth, but they do not 
take into account all of the cellular interactions that occur as a cell goes 
through the oncogenic and metastatic process. Before progressing to the 
main models of this review, it should be noted that rat and canine have 
been used for some important discoveries about spontaneous prostate 
lesions. They are not often favored by the PCa research community due 
either to inadequate genetic manipulation in case of rats or expensive 
price and pet affection in case of dogs. However, descriptions of these 
models can be found in the references [90,91]. Thus, mice have been 
the favored model organism in recapitulating various aspects of the 
disease process. Excellent reviews devoted solely to mouse models are 
available in the references [92,93]. Information provided in this section 
is summarized in Table 2.
Mouse surgery and xenograft models
The most widely utilized tool in PCa research is the use of human 
PCa cell lines transplanted into mice, referred to as xenograft or xeno-
transplantation. There are three modes of xenograft employed today: 
subcutaneous, orthotopic, and under the subrenal capsule (SRC). Each 
has its own costs and benefits.
Subcutaneous xenograft models were developed first utilizing the 
insertion of patient prostatic tissue into the shoulder of nude mice in the 
late 1970s by Schröder and colleagues at Erasmus University Rotterdam. 
This gave us the first transplantable tumor cell line, PC-82 [94]. The 
advantages of this model system include easy accessibility and less 
demanding technical expertise, as well as the amount of tumor tissue 
that can be introduced. The take is reportedly very low, owing to poor 
vascularization of the dermal tissue. Take rates vary in the literature in 
recent years from as low as 3% to as high as 58% [95]. Additionally, 
low to moderately aggressive tumors do not seem to thrive very well 
in this type of environment, as only highly aggressive tumors seem 
to account for the majority of tumors recovered from nude mice [96].
Orthotopic xenograft models allow for the introduction of can-
cerous prostatic tissue into the mouse prostate. Stephenson et al. first 
introduced this model in 1992. In their initial study they very clearly 
concluded that the subcutaneous, or any ectopic, model does not reveal 
the metastatic potential of implanted human PCa tissue. Additionally, 
this work was expanded by An and colleagues to show a high degree of 
lung and lymph node metastasis, the first such demonstration published 
in the literature [97]. The obvious advantages of this model include 
the relevance of the interactions between the implanted tissue and the 
organ of origin, as bolstered by the evidence that metastatic potential is 
increased not only in orthotopically implanted prostatic tissue but also 
other organs as well [98]. The take rate for this procedure is in a much 
more favorable, reported at nearly 72% [96]. This model also offers 
the advantage of implanting a wider range of tumor aggression levels, 
allowing for the investigation of tumorigenic and metastatic processes. 
The main disadvantages to this type of procedure include the skill set 
that is required for conducting the surgery and the limited amount of 
tissue that can be introduced into the mouse prostate. Additionally, 
androgen ablation therapy prior to tissue introduction causes such a 
large amount of prostatic regression that it makes implementation of 
some experimental designs practically impossible.
Table 2 . Common Mouse Models Used in Prostate Cancer Research.
Model Genetic Alteration Tumorigenic Time Course Metastasis Purpose Reference
Pten Cre recombinase to excise 
the coding sequence of Pten 
between two loxP sites
6 weeks to PIN formation; 9–29 
weeks for invasive carcinoma
Lymph nodes, lung Defined time course 
through PIN lesions
Wang, 2003 
[132]
TRAMP SV40 large/small t antigen 
driven using a prostate specific 
promoter PB; can combine 
ARR2 with PB to drive SV40 or 
a host of other molecules
Mild hyperplasia in 8–12 weeks, 
metastatic disease starting at 18 
weeks
Bone, lymph node, 
lung, adrenal gland, 
kidney
Fast time course to meta-
static disease
Greenberg,
1995 [109], 
Gingrich, 1996 
[110]
Hi Myc ARR2-PB promoter to drive 
high expression of c-myc with 
androgen responsiveness
3 months to PIN formation; 6 
months to invasive cancer
None noted [145] Defined time course; 
androgen sensitivity of 
promoter
Ellwood-Yen, 
2003 [128]
Lo Myc PB promoter to drive low 
expression of c-myc
6–12 months for PIN; 12 months 
or more for invasive cancer
None noted [146] Slower time course; 
allows for investigation 
of oncogenic/castration 
resistance drivers
Ellwood-Yen, 
2003 [128]
LADY LPB; -12kb/+28 region of the 
PB promoter used to solely 
drive expression of SV40 large 
T antigen
10–15 weeks for dysplasia, 
15–22 weeks for carcinoma in 
the 12T-7 (fast and slow)
Regional lymph 
nodes, liver, lung
Tumors demonstrate 
neuroendocrine differen-
tiation [147] considered 
a late event in tumori-
genesis
Kasper, 1998 
[126]
MPAKT -421/+28bp of PB driving the 
myr-HA-Akt1 construct
PIN lesions early in life; no 
invasive carcinoma detected up 
to 78 weeks
None reported Study the transformation 
of prostatic epithelial cells
Majumder, 2003 
[138]
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SRC xenografts are the most recent development in xenotransplanta-
tion. Initially introduced into the literature by Wang in 2005, they were 
able to successfully recover over 93% of tumors [96]. They note the 
caveat that there was a spread of recovery rates dependent on individual 
experience of the person performing the procedure, but this still illustrates 
that SRC grafting is a viable way to recover xenograft material. The 
authors postulate that this technique is so successful because of the high 
degree of vascularity to the tissue. It would be difficult to comment on 
the metastatic potential of this model, as searches on PubMed for the 
term “prostate cancer subrenal capsule” returns 31 hits. The majority of 
these publications are aimed at investigating the primary tumor itself and 
don’t comment on metastatic potential, although some studies, which 
are described in the references, do conclude that the investigation of 
metastatic genes is possible with this technique [99-101]. Despite the 
disadvantage of not being the native tissue from which the implanted 
tumor arises, SRC xenografts offer some exciting possibilities when 
combined with using patient tissue as the graft material. Wang and col-
leagues have recently commented on the utility of this system, pointing 
to the fact that such a high degree of tumors can be recovered using the 
SRC grafts [102]. They suggested that this could impact basic research 
on PCa, identification of metastatic driver genes, and the ability to tailor 
clinical therapy to the patient’s tumor biology [103-105]. Preclinical 
in vivo studies are difficult to translate to the bedside because of the 
homogeneity of cultured cell lines, which can be contrasted with the 
heterogeneity of different subpopulations of both cancer and stromal 
cells within a tumor mass. Next generation patient-derived PCa xenograft 
models allow the cancerous subpopulations of cells to express their 
dominance when transplanted into NOD/SCID mice, and therapy can 
be tested and tailored to the tumor biology depending on the tumor’s 
growth response. One organization that has been developing this avenue 
of investigation is the Living Tumor Laboratory [106].
Relevant to the topic of xenograft procedures, the issue of bioengi-
neered materials should be discussed. Substances such as Matrigel™, 
polyethylene glycol (PEG), collagen and sponge are often used in the 
creation of a cell suspension pre-procedure to allow a microenvironment 
hospitable for cancer cell growth. There is no question that these ma-
terials are useful in rendering a more faithful tumor microenvironment 
both in xenograft and 3-dimensional (3D) culture models. However, it 
is still being discussed in the field about the effect that these materials 
have on gene expression profiles and responsiveness to androgen. Work 
by Lang et al. seems to indicate that Matrigel™ induces morphological 
changes that may be indicative of gene expression profile changes 
[107]. More recent studies have indicated more finely tuned materials 
such as PEG hydrogels, containing arginine-glycine-aspartate (RGD) 
and matrix metalloproteinase (MMP) cleavage sites, provide a micro-
environment that better recapitulates native tissue environment [108]. 
This consideration should be made particularly if hormone sensitivity 
or drug discovery studies are being conducted.
TRAMP
Norman Greenberg and his group first developed this mouse in 1995 
with subsequent description of metastatic disease in these animals by 
28 weeks of age [109,110]. Spontaneously occurring prostate lesions 
were observed in limited types of animals; however, rats seem to form 
spontaneous adenocarcinoma on a regular basis [111,112]. Subsequent 
investigation showed that rat prostate contained a prostate specific 
promoter probasin (PB or rPB) that directed an androgen sensitive 
transcriptional program [113]. When considering the responsiveness of 
a mouse model to the development of PCa, the consideration and choice 
of promoter is absolutely essential and is the main distinguishing feature 
between different models. Greenberg and his group were able to drive 
the expression of the SV40 large T antigen using the upstream 426 bp 5’ 
flanking region and 28 bp of the 5’ untranslated region. Experimentation 
with chloramphenicol acetyl transferase and luciferase reporter assays 
demonstrated that the -426/+28 PB promoter contained two androgen 
receptor binding sites (ARBS) in the regions of -236 to -223 and -140 to 
-117, respectively, with the region containing both of these sites (-244 to 
-40) referred to as ARR [113]. The oncogenic effects of the SV40 protein 
are primarily interactions with the tumor suppressors p53 and Rb. The 
loss of both of these proteins has been implicated in the development 
and progression of prostate lesions [114-117]. Using the composite of 
two linked ARR regions, referred to as ARR2, the combination ARR2-
PB construct has been used to investigate a wide range of molecules 
and their role in the initiation and progression of PCa. Such examples 
include the growth signaling molecule Ras, hepsin, the ubiquitin E3 
ligase SCF (SKP2, an F box protein), and FGF8 [118-121]. Bigenic 
models have also been developed. Fibroblast growth factor 2 (FGF2) 
null mice have been crossed with TRAMP animals to investigate the 
role of that factor in tumor development, drawing upon observations of 
high expression of FGF2 in PC3 and DU-145 cells [122]. This model 
is generally regarded with very high utility, as the progression through 
PIN lesions to malignant disease is on a predictable time course that 
mimics human oncogenic milestones. However, the TRAMP model 
may not be the best suited for oncogenic studies. It is well purposed for 
studies of treatment and prevention. Recent studies of this model have 
shown that many tumors display neuroendocrine (NE) differentiation, 
suggesting that this model is likely a model of small cell carcinoma, 
rather than adenocarcinoma [123,124].
LADY
One of the more insidious aspects of PCa is the fact that several 
cell types can contribute to the initiation or sustenance of a tumor. 
The typical prostate tissue architecture is composed of stroma, basal 
and luminal cells. However, in the consideration of the molecular and 
cellular mechanisms to account for castration resistance, scientists and 
physicians made the discovery that the nervous system makes a contri-
bution to prostate tissue architecture in the form of NE cells. NE cells 
are thought to be paracrine signaling cells that control the growth of 
prostatic epithelium [125], and due to their lack of androgen receptor are 
thought to be a driver in castration resistance. The work of two groups 
led to the development of a mouse model that faithfully recapitulated 
the progression of prostatic intraepithelial neoplasia all the way to 
malignant disease [126,127]. The genetic modifications of the LADY 
model are similar to the TRAMP model, with a larger 12 kb region of 
the rPB promoter (referred to as the LPB) situated upstream of the sole 
SV40 large T antigen. The LADY model also has the distinction of 
containing the d1 2005 deletion mutation in the small t antigen, elimi-
nating its expression. It was for the purpose of investigating the role of 
neuroendocrine differentiation that the LADY model was developed, 
and Masumori et al. were able to successfully demonstrate the presence 
of neuroendocrine differentiation in metastatic lesions [127].
Hi/Lo-Myc mouse
Sawyers and colleagues published their work on using two constructs 
based on using the PB promoter to drive prostate specific expression 
of c-Myc oncogene. One construct, designated Lo-myc, uses the PB 
promoter alone to drive c-Myc expression. The other, designated Hi-
myc, uses PB coupled with a sequence of the ARR2 promoter, both 
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of which lie upstream of the human c-Myc gene to drive progression 
from mouse prostatic intraepithelial neoplasia (mPIN) to invasive ade-
nocarcinoma [128]. An important distinction between these two models 
is the androgen responsiveness of the Hi-myc model. The ARR2 is 
androgen responsive, which has the implication of reversing mPIN by 
silencing expression of the transgene in mice 3 months post-castration 
and causing regression, but not elimination, of prostate tumors in mice 
out to 5 months post-castration. The Lo-myc model displays no such 
responsiveness [128].
Figure 1. Intratibial cancer 
cell injection mouse model. 
A. X-ray image taken of a nor-
mal mouse tibia pre-procedure 
on the contralateral side with the 
radiolucent bone marrow cav-
ity visible on the proximal end 
of the bone. B. X-ray image of 
a mouse tibia with a 21-gauge 
needle inserted into the proximal 
bone marrow cavity. C. Results 
of successful injection of PC3 
cells expressing luciferase (and 
an injection of D-luciferin) using 
an IVIS (IVIS® Illumina XRMS 
Series III, PerkinElmer, Waltham, 
MA, USA).
Pten knockout
 PTEN ablation has been shown to be an early event in PCa initi-
ation and progression [129], and new technologies have allowed for 
this molecule to be knocked out in a mouse model. Briefly, it was 
discovered that Cre recombinase, a nuclease in the bacteriophage P1, 
recognized conserved sequences called loxP sites and excised any 
genetic information encoded between two of these sites [130]. Thus, 
mouse embryos can be engineered to have loxP sites flanking a gene 
of interest (a “floxed” gene). When Cre and a floxed gene are present 
in the same organism, the Cre will excise the floxed gene using loxP 
recognition, either in a constitutive manner or inducible manner through 
the use of estrogen compounds. A valuable tool in the investigation of 
PCa has been the Pten null mouse [131]. The value of this model is 
that the animal demonstrates the range of conditions seen in human 
subjects, progressing through low grade PIN to invasive carcinoma 
and metastasis in only 12 weeks [132]. There is also the benefit of Cre 
expression being predominantly tissue specific with highest expression 
seen in the lateral prostate [132]. The Pten knockout model has been 
successfully used to ascertain the contributions that IL-17 makes to 
the tumor microenvironment in a Pten and IL-17 receptor C double 
knockout model [133,134]. Additional bigenic models have also been 
developed using the Pten knockout background. Cross breeding between 
Pten heterozygotes and TRAMP, Nkx3.1, and p27Kip1 are all currently 
being implemented in experimentation [135-137].
MPAKT
The mouse prostate Akt (MPAKT) model was developed to study the 
role of protein kinase B (Akt) in the transformation of prostate epithelial 
cells [138]. The alteration to this animal’s genome is the introduction 
of the coding sequence for Akt1 along with a myristolation sequence 
(myr) and a hemagluttinin (HA) epitope for proper targeting of the 
protein to the inner leaflet of the cell membrane. These elements are 
combined to create the PB-myr-HA-Akt1 construct [139]. PIN lesions 
were described via immunohistochemical (IHC) analysis early on in the 
mouse’s life, but no invasive carcinoma was detected in any animals 
even after 78 weeks. The authors who originally developed this model 
think that there are more oncogenic factors at play in the transforma-
tion of prostate epithelium than just constitutive activation of the Akt 
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pathway. One interesting observation is the similarity of MPAKT and 
haploinsufficient Pten PIN lesions.
Metastatic models
Several important models for studying PCa metastasis are currently 
available. In an effort to model the bone metastatic tumor growth, the 
intratibial injection model was developed. PCa cells can be suspended 
in phosphate-buffered saline or Matrigel™ and directly injected into 
the tibias of genetically manipulated or WT mice. Imaging technologies 
can be applied to track changes in bone lesions and morphology of the 
tissue itself [140]. In vivo imaging system (IVIS) technologies have 
recently been implemented to track lesion growth, taking advantage 
of stable luciferase expression in PCa cell lines. An example of whole 
mouse in vivo imaging can be found in Figure 1.
Tail vein cancer cell injection is another method of assessing the 
role of different molecules in metastasis. The interactions between 
circulating tumor cells and the endothelium are extremely important 
factors in this process, and tail vein injections allow the delivery of a 
bolus of cancer cells into the bloodstream in a tolerable volume [141]. 
An excellent example of the utility of this model can be found in the 
recent publication by LeBeau and colleagues [142].
The other option for introducing cancer cells into the bloodstream 
is the use of intracardiac injection. Campbell and colleagues have in-
troduced a good description of the protocol with accompanying visual 
documentation [140]. Jenkins et al. have combined the strategies of 
intracardiac inoculation of genetically altered PC-3M-luc-C6 cells to 
track propagation of metastasis [143].
Conclusions
When juxtaposed with the depth and breadth of characterization of 
breast cancer, the field of PCa research has been lagging behind in the 
understanding of how molecular phenotype affects clinical parameters 
and prognosis. Markers commonly used to diagnose this disease, such 
as PSA, have been met with opposition to its continued widespread 
use. Significant molecules in the initiation and progression of PCa, 
specifically AR, have yet to be fully elucidated in terms of their con-
tribution to castration resistance. It is for this reason that investigation 
needs to continue, specifically to better understand the drivers behind 
oncogenesis, how this affects clinical course, and to provide therapeutic 
targets. The techniques and models described herein are essential tools 
for bolstering that understanding. Perhaps the biggest challenge in the 
field is developing an animal model that faithfully recapitulates bone 
metastasis. Due to the high degree of morbidity and mortality that is 
associated with this type of tumor progression, an animal model that 
reliably seeds tumor cells from prostate to bone would be of substantial 
value, both clinically and scientifically [144]. Such a model would al-
low for investigation of circulating tumor cell/bone matrix interactions 
and potential therapeutic targets for metastatic prevention. As a final 
note, a thorough investigation of cell lines reveals few in vitro models 
being isolated from African-American men that are widely available 
to the research community. Due to the increased incidence of PCa in 
this population, we would be remiss if not making a concerted effort 
to correct this oversight.
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